Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL. ...Middle East

NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic...

Hence then, the article about bioheng biotech received orphan drug designation from the u s fda for the treatment of t all was published today ( Sunday 20/06/2021 - 06:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL. )

Also on site :

• Contractor that cut back ancient oak in London park identified
• Jennifer Siebel Newsom’s Parenting Tips Include Dolls for Boys and Gender-Swapping Male Book Characters
• Myanmar’s coup leader elected president by pro-military parliament